An increase in funding for R&D activities pertaining to gene therapy and growth in awareness regarding gene therapy drives the global market growth. In addition, an increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in the prevalence of cancer fuel the growth of the market. However, the high cost associated with the treatment and unwanted immune responses is expected to hamper the market growth in upcoming years.
The gene therapy market is segmented on the basis of vector type, gene type, application, and region. On the basis of vector type, it is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia virus, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. By therapy type, the market is classified into ex vivo therapy and in vivo therapy. By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.
By application, it is divided into oncological disorders, rare diseases, neurological disorders, and other diseases. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in the global gene therapy market include Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono Genentech, Shanghai Sunway Biotech Co., Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Amgen Inc., Astellas Therapeutics, Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene therapy market analysis from 2020 to 2030 to identify the prevailing gene therapy market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the gene therapy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global gene therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Vector Type
- Viral Vector
- Non Viral Vector
By Therapy
- In Vivo Therapy
- Ex Vivo Therapy
By Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth factors
- Receptors
- Others
By Application
- Oncological Disorders
- Rare Diseases
- Neurological Disorders
- Other Diseases
By Region
- North America
- Europe
- Asia-Pacific
- LAMEA
Key Market Players
- Novartis AG
- Gilead Sciences.
- Jazz Pharmaceuticals
- Orchard Therapeutics.
- Bristol-Myers Squibb.
- Amgen Inc.
- Shenzhen SiBiono GeneTech
- Shanghai Sunway Biotech Co. Ltd.
- Adaptimmune Therapeutics plc
- Adverum Biotechnologies Inc.
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Astellas Therapeutics Inc.
- Bluebird Bio, Inc.
- CRISPR Therapeutics AG
- Intellia Therapeutics, Inc.
- REGENXBIO Inc.
- Sangamo Therapeutics, Inc.
- Uniqure N. V., Voyager Therapeutics, Inc.
- Merck and Co Inc.
- Dendron Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Executive Summary
According to this report titled, 'Gene Therapy Market,' the Gene Therapy Market Size was valued at $6.0 billion in 2020 and is estimated to reach $46.5 billion by 2030, growing at a CAGR of 22.8% from 2021 to 2030.Gene therapies are treatments that are applicable to a broad range of diseases. They radically treat the cause of the diseases, instead of only relieving the symptoms. Furthermore, they may be effective on a wide range of previously untreated diseases, such as hematological, ocular, neurodegenerative diseases, and several cancers. For example, adeno-associated AAV2 vectors carrying the therapeutic gene (RPE65) administered via intra-retinal injection resulted in improved vision for people with Leber’s congenital amaurosis. These therapies can be applied either in combination with cell products and through an ex vivo treatment mode, such as Strimvelis or directly administered in vitro, for example, Glybera. Several vectors present clinically relevant options, including adenovirus (AV), adeno-associated virus (AAV), and lentivirus.
High investments for R&D activities pertaining to gene therapy and an increase in awareness regarding gene therapy boost the Gene Therapy Market Growth In addition, an increase in government support, ethical acceptance of gene therapy for cancer treatment, and a rise in the prevalence of cancer are other factors expected to fuel the Gene Therapy Market Growth. However, the high cost associated with the treatment and unwanted immune responses is expected to impede the growth of the market.
The Gene Therapy Industry is segmented on the basis of vector type, gene type, application, and region. On the basis of vector type, it is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia virus, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. By therapy type, the market is classified into ex vivo therapy and in vivo therapy. By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.
By application, it is divided into oncological disorders, rare diseases, neurological disorders, and other diseases. Region-wise, Gene Therapy Market Analysis is done across North America, Europe, Asia-Pacific, and LAMEA.
By vector type, the non-viral vector segment is the highest Gene Therapy Market Share and accounted for the largest segment in 2020 and is expected and is anticipated to be a lucrative market due to technological advancements in these vectors with positive results during the preclinical and clinical trials for the treatment of various diseases.
By gene type, the antigen segment dominated the market in 2020 and the deficiency segment is the fastest-growing segment during the forecast period. By application, the oncological disorders segment dominated the market in 2020 and is anticipated to be a lucrative market.
In 2020, North America accounted for the maximum Gene Therapy Market Share, owing to a high prevalence rate of cancer, the presence of high disposable income, and an increase in funding for R&D activities associated with gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to a rise in the incidence rate of cancer, an increase in government initiatives to improve healthcare infrastructure, and a rise in healthcare expenditure.
The key players operating in the global Gene Therapy Industry include Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono Genentech, Shanghai Sunway Biotech Co., Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Amgen Inc., Astellas Therapeutics, Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Unique N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.
Key findings of the Study
- By vector type, the non-viral vector segment was the highest contributor to Gene Therapy Market Size in 2020.
- By gene type, the antigen gene segment type dominated the market in 2020.
- By application, the oncological disorders segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
- Region-wise, North America garnered the largest revenue share in 2020; however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Novartis AG
- Gilead Sciences.
- Jazz Pharmaceuticals
- Orchard Therapeutics.
- Bristol-Myers Squibb.
- Amgen Inc.
- Shenzhen SiBiono GeneTech
- Shanghai Sunway Biotech Co. Ltd.
- Adaptimmune Therapeutics plc
- Adverum Biotechnologies Inc.
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Astellas Therapeutics Inc.
- Bluebird Bio, Inc.
- CRISPR Therapeutics AG
- Intellia Therapeutics, Inc.
- REGENXBIO Inc.
- Sangamo Therapeutics, Inc.
- Uniqure N. V., Voyager Therapeutics, Inc.
- Merck and Co Inc.
- Dendron Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...